Functions of Some Sirtuins and Their effect on Type 2 Diabetes Mellitus in Iraqi Patients

Rasha Jaber  Shamkhi

doi:10.17605/cajmns.v6i4.2853

Rasha Jaber Shamkhi Martyr Qudama Qasim Farhan Secondary School

DOI: https://doi.org/10.17605/cajmns.v6i4.2853

Keywords: SIRT1gene, T2DM, Real-TimePCR

Abstract

This paper intended to estimate the interrelationship among the SIRT1 gene expression and type 2 diabetes mellitus (T2DM) in a sample of individuals from Wasit City, Iraq in collaboration with AL-Karama Teaching Hospital. A total of 60 participants (40 diabetic patients and 20 healthy controls), aged between 40 and 70 years, were enrolled. Blood samples were analyzed using RT-PCR to assess gene expression and ELISA to measure protein concentration in serum .SIRT1 gene expression was significantly upregulated in diabetic patients, as indicated by a lower ΔCt value, with strong statistical significance (P = 0.001). No significant difference in SIRT1 protein levels in the serum among the diabetic and controlling groups (P = 0.85). No significant gender-based differences were noticed in SIRT1 protein concentrations . The findings suggest a notable increase in SIRT1 gene expression in individuals with T2DM, potentially indicating a regulatory role of this gene in the disease. However, the lack of corresponding changes in protein levels warrants further studies to clarify the underlying mechanisms.

References

M. Roden and G. I. Shulman, “The integrative biology of type 2 diabetes,” Nature, vol. 576, no. 7785, 2019.

M. G. Tinajero and V. S. Malik, “An update on the epidemiology of type 2 diabetes: A global perspective,” Endocrinol. Metab. Clin. N. Am., vol. 50, pp. 337–355, 2021.

J. Reed, S. Bain, and V. Kanamarlapudi, “A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives,” Diabetes Metab. Syndr. Obes., vol. 14, pp. 3567–3602, 2021.

L. Chen et al., “Maximizing efficiency and cost‐effectiveness of Type 2 diabetes screening: the AusDiab study,” Diabet. Med., vol. 28, no. 4, pp. 414–423, 2011.

S. Alam et al., “Diabetes mellitus: Insights from epidemiology, biochemistry, risk factors, diagnosis, complications and comprehensive management,” Diabetology, vol. 2, pp. 36–50, 2021.

P. Alonso-Magdalena, A. B. Ropero, S. Soriano, I. Quesada, and A. Nadal, “Bisphenol-A: a new diabetogenic factor?,” Hormones, vol. 9, no. 2, pp. 118–126, 2010.

K. Ogurtsova et al., “IDF diabetes atlas: Global estimates for the prevalence of diabetes for 2015 and 2040,” Diabetes Res. Clin. Pract., vol. 128, pp. 40–50, 2017.

G. Riccardi, M. Vitale, and R. Giacco, “Treatment of diabetes with lifestyle changes: Diet,” in Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment, Cham: Springer, 2018, pp. 1–16.

“Lifestyle Management: Standards of medical care in diabetes—2018,” Diabetes Care, vol. 41, suppl. 1, pp. S38–S50, 2018.

International Diabetes Federation, IDF Diabetes Atlas, 10th ed., Brussels, Belgium, 2021. [Online]. Available: https://www.diabetesatlas.org

K. He, J. C. Shi, and X. M. Mao, “Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients,” Ther. Clin. Risk Manag., vol. 10, pp. 505–511, 2014.

F. K. Huynh, K. A. Hershberger, and M. D. Hirschey, “Targeting sirtuins for the treatment of diabetes,” Diabetes Manage., vol. 3, no. 3, pp. 245–257, 2013.

S. A. Samant et al., “The histone deacetylase SIRT6 blocks myostatin expression and development of muscle atrophy,” Sci. Rep., vol. 7, no. 1, p. 11877, 2017.

C. Ling and T. Rönn, “Epigenetics in human obesity and type 2 diabetes,” Cell Metab., vol. 29, no. 5, pp. 1028–1044, 2019.

M. M. Poulsen et al., “Resveratrol and inflammation: challenges in translating pre-clinical findings to improved patient outcomes,” Biochim. Biophys. Acta Mol. Basis Dis., vol. 1852, no. 6, pp. 1124–1136, 2015.

L. Guarente, “Sirtuins, aging, and medicine,” N. Engl. J. Med., vol. 364, pp. 2235–2244, 2011.

X. Hui et al., “Adipocyte SIRT1 controls systemic insulin sensitivity by modulating macrophages in adipose tissue,” EMBO Rep., vol. 18, pp. 645–657, 2017.

P. Gomes, T. Fleming Outeiro, and C. Cavadas, “Emerging role of sirtuin 2 in the regulation of mammalian metabolism,” Trends Pharmacol. Sci., vol. 36, pp. 756–768, 2015.

R. H. Houtkooper, E. Pirinen, and J. Auwerx, “Sirtuins as regulators of metabolism and healthspan,” Nat. Rev. Mol. Cell Biol., vol. 13, pp. 225–238, 2012.

W. Giblin, M. E. Skinner, and D. B. Lombard, “Sirtuins: guardians of mammalian healthspan,” Trends Genet., vol. 30, pp. 271–286, 2014.

Y. Colak et al., “SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease,” Med. Sci. Monit., vol. 17, pp. HY5–HY9, 2011.

J. S. Mohamed et al., “MicroRNA-149 inhibits PARP-2 and promotes mitochondrial biogenesis via SIRT-1/PGC-1alpha network in skeletal muscle,” Diabetes, vol. 63, pp. 1546–1559, 2014.

L. Papa and D. Germain, “SirT3 regulates the mitochondrial unfolded protein response,” Mol. Cell Biol., vol. 34, pp. 699–710, 2014.

M. D. Hirschey et al., “SIRT3 regulates mitochondrial protein acetylation and intermediary metabolism,” Cold Spring Harb. Symp. Quant. Biol., vol. 76, pp. 267–277, 2011.

A. P. Rolo and C. M. Palmeira, “Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress,” Toxicol. Appl. Pharmacol., vol. 212, pp. 167–178, 2006.

L. Guarente, “Sirtuins and beta-cell function,” Diabetes Obes. Metab., vol. 9, suppl. 2, pp. 23–27, 2007.

N. Ahuja et al., “Regulation of insulin secretion by SIRT4, a mitochondrial ADP-ribosyltransferase,” J. Biol. Chem., vol. 282, pp. 33583–33592, 2007.

L. Bordone and L. Guarente, “Sirtuins and beta-cell function,” Diabetes Obes. Metab., vol. 9, suppl. 2, pp. 23–27, 2007.

N. Nasrin et al., “SIRT4 regulates fatty acid oxidation and mitochondrial gene expression in liver and muscle cells,” J. Biol. Chem., vol. 285, pp. 31995–32002, 2010.

C. Dong et al., “Association of the sirtuin and mitochondrial uncoupling protein genes with carotid plaque,” PLoS ONE, vol. 6, no. 11, p. e27157, 2011.